Idiopathic pulmonary fibrosis - novel approach on future treatment

PACEK, Katarzyna, PIEKARSKA, Małgorzata, PIKULICKA, Agata, JEDLINA, Klaudia, SZULC, Izabela, KASPERSKI, Radosław, SWACHA, Weronika & MAKOWSKA, Karolina. Idiopathic pulmonary fibrosis - novel approach on future treatment. Journal of Education, Health and Sport. 2023;13(2):268-272. eISSN 2391-8306. DOI https://dx.doi.org/10.12775/JEHS.2023.13.02.039 https://apcz.umk.pl/JEHS/article/view/41034 https://zenodo.org/record/7510020 The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of December 21, 2021. No. 32343. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical Culture Sciences (Field of Medical sciences and health sciences); Health Sciences (Field of Medical Sciences and Health Sciences). Punkty Ministerialne z 2019 - aktualny rok 40 punktów. Załącznik do komunikatu Ministra Edukacji i Nauki z dnia 21 grudnia 2021 r. Lp. 32343. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu). © The Authors 2023; This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 24.11.2022. Revised: 21.12.2022. Accepted: 06.01.2023. Idiopathic pulmonary fibrosis – novel approach on future treatment Katarzyna Pacek, ORCID: 0000-0001-6947-558X, kasia.pacek1@gmail.com, Centralny Szpital Kliniczny MSWiA w Warszawie, ul. Wołoska 137, 02-507 Warszawa Małgorzata Piekarska, ORCID: 0000-0001-5055-4923, piekarska13@gmail.com, Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego SPZOZ w Lublinie, Al. Kraśnicka 100, 20-718 Lublin Agata Pikulicka, ORCID: 0000-0003-1693-8127, agapikulicka@gmail.com, Szpital Solec, ul. Solec 93, 00-382, Warszawa Klaudia Jedlina, ORCID: 0000-0002-2363-2620, klaudiajedlina@gmail.com, Centralny Szpital Kliniczny MSWiA w Warszawie, ul. Wołoska 137, 02-507 Warszawa, Izabela Szulc, ORCID: 0000-0002-2262-6886, izabelaszulc4@gmail.com,Szpital Praski P.W. Przemienienia Pańskiego w Warszawie, aleja "Solidarności" 67, 03-401 Warszawa Radosław Kasperski, ORCID: 0000-0002-7364-3205, r.kasperski95@gmail.com, Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego SPZOZ w Lublinie, Al. Kraśnicka 100, 20-718 Lublin Weronika Swacha, ORICID: 0000-0002-1865-5967, weronka6@gmail.com, Mazowieckie Centrum Stomatologii w Warszawie, ul.Nowy Zjazd 1, 00-301 Warszawa Karolina Makowska, ORCID: 0000-0001-5467-3137, makowska.karolinaa@gmail.com, Uniwersytet Medyczny w Lublinie, Aleje Racławickie 1, 20-059 Lublin ABSTRACT Introduction Idiopathic pulmonary fibrosis (IPF) is a fatal pulmonary disease that leads to progressive fibrosis and extremely poor resaults.. Since the etiology is unknown, there are highly limited options of the IPF treatment. The researchers are trying to discover the most valuable targets, leading them to the agents registered in different conditions or not registered as any other treatment. This innovative approach can result in IPF being determined as not fatal. Purpose The purpose of our review is to present possible future treatment of idiopathic pulmonary fibrosis and point out the promising targets that could lead the researchers to the development of better IPF management. Materials and methods We have reviewed the literature from the PubMed database searching for clinical trials, meta analysis and randomized controlled trials from the past 5 years. The keywords we agreed on offered us the most informative articles and made us hope for the further development of our article. Results Our review shows that there are new targets that could significantly benefit IPF treatment. However, the means we presented in our review need more research to prove its safeness, effectiveness in slowing down the decline of the FVC, improving patients’ physical efficiency, their saturation level and most importantly their ability to stop the continuous fibrosis of the lungs. Conclusions The only treatment registered for IPF are nintedanib and pirfenidone, but the researchers continue the exploration of new possible measures to improve the survival rate and quality of life of the patients suffering from this fatal disease. Key words idiopathic pulmonary fibrosis; pamrevlumab; lung transplantation; senotherapeutics; recombinant human pentraxin 2